Literature DB >> 25740453

Effects of continuous infusion of low-dose human atrial natriuretic peptide (hANP) on the lungs during cardiac surgery.

Ikuko Shibasaki1, Hirotsugu Fukuda, Yasuyuki Yamada, Toshiyuki Kuwata, Takayuki Hori, Hironaga Ogawa, Go Tsuchiya.   

Abstract

OBJECTIVE: The objective of this study was to determine the effects of a continuous infusion of low-dose hANP on the lungs during cardiac surgery in patients under cardiopulmonary bypass (CPB).
METHODS: We analyzed 30 consecutive cases of cardiac surgery performed at our hospital from 2007-2008. The patients were divided into a group that received hANP (hANP group) or a group that received saline and no hANP (N-hANP group). We measured various parameters before and after surgery using a PiCCO monitor. RESULT: There were no differences in the preoperative characteristics between the groups, although urine volume during the operation was significantly greater in the hANP group. After surgery, there were no significant differences between the groups in cardiac output index (CI), global enddiastolic volume index (GEDVI), intrathoracic blood volume index (ITBI), pulmonary blood volume index (PBI), extravascular lung water index (ELWI) and pulmonary vascular permeability index (PVPI), total protein, and creatine. In contrast, interleukin-6 (IL-6) and renin were significantly lower, and albumin was significantly higher in the hANP group.
CONCLUSION: We found that low-dose hANP during open cardiac surgery inhibited the secretion and plasma activity of IL-6 and renin. Although there were no differences in lung circulatory parameters such as the amount of fluid in the pulmonary blood vessels between the two groups, we believe that the strong diuretic effect of hANP reduced third-space fluid retention caused by CPB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25740453      PMCID: PMC4904873          DOI: 10.5761/atcs.oa.14-00261

Source DB:  PubMed          Journal:  Ann Thorac Cardiovasc Surg        ISSN: 1341-1098            Impact factor:   1.520


  19 in total

1.  Antihypertensive and hypotensive effects of atrial natriuretic factor in men.

Authors:  A B Weder; M A Sekkarie; M Takiyyuddin; N J Schork; S Julius
Journal:  Hypertension       Date:  1987-12       Impact factor: 10.190

2.  Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP).

Authors:  K Kangawa; H Matsuo
Journal:  Biochem Biophys Res Commun       Date:  1984-01-13       Impact factor: 3.575

3.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs.

Authors:  T Maack; D N Marion; M J Camargo; H D Kleinert; J H Laragh; E D Vaughan; S A Atlas
Journal:  Am J Med       Date:  1984-12       Impact factor: 4.965

4.  Calcineurin-nuclear factor of activated T cells pathway-dependent cardiac remodeling in mice deficient in guanylyl cyclase A, a receptor for atrial and brain natriuretic peptides.

Authors:  Takeshi Tokudome; Takeshi Horio; Ichiro Kishimoto; Takeshi Soeki; Kenji Mori; Yuhei Kawano; Masakazu Kohno; David L Garbers; Kazuwa Nakao; Kenji Kangawa
Journal:  Circulation       Date:  2005-06-06       Impact factor: 29.690

5.  Inhibitory effect of natriuretic peptides on aldosterone synthase gene expression in cultured neonatal rat cardiocytes.

Authors:  Teruhiko Ito; Michihiro Yoshimura; Shota Nakamura; Masafumi Nakayama; Yukio Shimasaki; Eisaku Harada; Yuji Mizuno; Megumi Yamamuro; Masaki Harada; Yoshihiko Saito; Kazuwa Nakao; Hiroki Kurihara; Hirofumi Yasue; Hisao Ogawa
Journal:  Circulation       Date:  2003-02-18       Impact factor: 29.690

6.  Experimental investigation of direct myocardial protective effect of atrial natriuretic peptide in cardiac surgery.

Authors:  Shinji Wakui; Akira Sezai; Gero Tenderich; Mitsumasa Hata; Syunji Osaka; Yoshiki Taniguchi; Reiner Koerfer; Kazutomo Minami
Journal:  J Thorac Cardiovasc Surg       Date:  2009-11-11       Impact factor: 5.209

7.  Results of low-dose carperitide infusion in high-risk patients undergoing coronary artery bypass grafting.

Authors:  Akira Sezai; Kin-ichi Nakata; Mitsuru Iida; Isamu Yoshitake; Shinji Wakui; Hirokaki Hata; Motomi Shiono
Journal:  Ann Thorac Surg       Date:  2013-05-20       Impact factor: 4.330

8.  Efficacy of continuous low-dose hANP administration in patients undergoing emergent coronary artery bypass grafting for acute coronary syndrome.

Authors:  Akira Sezai; Mitsumasa Hata; Shinji Wakui; Tetsuya Niino; Tadateru Takayama; Atsushi Hirayama; Satoshi Saito; Kazutomo Minami
Journal:  Circ J       Date:  2007-09       Impact factor: 2.993

9.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials.

Authors:  Masafumi Kitakaze; Masanori Asakura; Jiyoong Kim; Yasunori Shintani; Hiroshi Asanuma; Toshimitsu Hamasaki; Osamu Seguchi; Masafumi Myoishi; Tetsuo Minamino; Takahiro Ohara; Yoshiyuki Nagai; Shinsuke Nanto; Kouki Watanabe; Shigeru Fukuzawa; Atsushi Hirayama; Natsuki Nakamura; Kazuo Kimura; Kenshi Fujii; Masaharu Ishihara; Yoshihiko Saito; Hitonobu Tomoike; Soichiro Kitamura
Journal:  Lancet       Date:  2007-10-27       Impact factor: 79.321

10.  Guanylyl cyclase-A inhibits angiotensin II type 1A receptor-mediated cardiac remodeling, an endogenous protective mechanism in the heart.

Authors:  Yuhao Li; Ichiro Kishimoto; Yoshihiko Saito; Masaki Harada; Koichiro Kuwahara; Takehiko Izumi; Nobuki Takahashi; Rika Kawakami; Keiji Tanimoto; Yasuaki Nakagawa; Michio Nakanishi; Yuichiro Adachi; David L Garbers; Akiyoshi Fukamizu; Kazuwa Nakao
Journal:  Circulation       Date:  2002-09-24       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.